139 related articles for article (PubMed ID: 22285805)
1. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.
Levitsky J; Fiel MI; Norvell JP; Wang E; Watt KD; Curry MP; Tewani S; McCashland TM; Hoteit MA; Shaked A; Saab S; Chi AC; Tien A; Schiano TD
Gastroenterology; 2012 May; 142(5):1132-1139.e1. PubMed ID: 22285805
[TBL] [Abstract][Full Text] [Related]
2. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy.
Chan C; Schiano T; Agudelo E; Paul Haydek J; Hoteit M; Laurito MP; Norvell JP; Terrault N; Verna EC; Yang A; Levitsky J
Am J Transplant; 2018 Oct; 18(10):2506-2512. PubMed ID: 30075485
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of recurrent hepatitis C infection after liver transplantation].
Filipec Kanizaj T; Colić Cvrlje V; Mrzljak A; Ostojić R
Acta Med Croatica; 2009 Dec; 63(5):451-7. PubMed ID: 20198907
[TBL] [Abstract][Full Text] [Related]
6. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report.
Nakano R; Ohira M; Ishiyama K; Ide K; Kobayashi T; Tahara H; Shimizu S; Arihiro K; Imamura M; Chayama K; Tanaka Y; Ohdan H
Transplant Proc; 2017 Sep; 49(7):1634-1638. PubMed ID: 28838454
[TBL] [Abstract][Full Text] [Related]
7. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
[TBL] [Abstract][Full Text] [Related]
8. Early and extended therapy for recurrent hepatitis C after liver transplantation.
García-Pajares F; Almohalla C; Lorenzo Pelayo S; Ruiz Zorrilla R; Pinto P; Ramos C; Sanchez Antolin G; Paton AC
Transplant Proc; 2012; 44(6):1571-3. PubMed ID: 22841217
[TBL] [Abstract][Full Text] [Related]
9. Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy.
Kallwitz ER
World J Gastroenterol; 2013 Jan; 19(2):158-60. PubMed ID: 23345937
[TBL] [Abstract][Full Text] [Related]
10. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
Nair S; Waters B
Exp Clin Transplant; 2014 Apr; 12(2):117-22. PubMed ID: 24702143
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?
Merli M; Gentili F; Giusto M; Attili AF; Corradini SG; Mennini G; Rossi M; Corsi A; Bianco P
Dig Liver Dis; 2009 May; 41(5):345-9. PubMed ID: 19162574
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
[TBL] [Abstract][Full Text] [Related]
16. Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
Singhal A; Jain AB; Burke M; Black M
Exp Clin Transplant; 2010 Sep; 8(3):214-9. PubMed ID: 20716039
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
[TBL] [Abstract][Full Text] [Related]
18. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
19. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation.
Gordon FD; Kwo P; Ghalib R; Crippin J; Vargas HE; Brown KA; Schiano T; Chaudhri E; Pedicone LD; Brown RS
J Clin Gastroenterol; 2012 Sep; 46(8):700-8. PubMed ID: 22739223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
